OneOncology’s NGS Testing Abstracts Accepted for Oral Presentation at ASCO 2023
Thomas Stricker, M.D., Ph.D., Presents Clinical Value of Timely Targeted Therapy (TT) for Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC) with Actionable Driver Oncogenes
Gregory Vidal, M.D., Ph.D., Presents Practice-and-Provider-Level Inequities in Next-Generation Sequencing (NGS) Testing by Race/Ethnicity for Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC) Treated in the Community Setting
Nashville, TN – May 22, 2023 – OneOncology Clinical Investigators, Thomas Stricker, MD, Ph.D., Medical Director of Precision Medicine for OneOncology, and Gregory Vidal, M.D., Ph.D., Chair of Breast Cancer Disease Group, OneOncology, and Director of Clinical Research, West Cancer Center & Research Institute, are each the first authors on two Abstracts accepted for oral presentation at ASCO 2023. Both will present their Abstracts during the June 6 session from 8:00 AM – 11:00 AM.
Dr. Stricker is the first author of Abstract 6507, Clinical Value of Timely Treatment for Advanced Non-Small Cell Lung Cancer Patients (aNSCLC) with Actionable Driver OncoGenes.
Dr. Vidal is the first author of Abstract 6508. Practice-and Provider-Level Inequities in Next-Generation Sequencing Testing by Race/Ethnicity for Patients with aNSCLC in the Community Setting
“OneOncology’s clinical research team and our partners will unveil insightful and actionable NGS-testing research that can advance better health outcomes and improve health equity,” said Davey Daniel, MD., OneOncology Chief Medical Officer.
Both studies were conducted with Genentech, a member of the Roche Group, as part of a multi-year strategic partnership to collaborate on various clinical trials, scientific research, and real-world data studies advancing personalized cancer care in community oncology centers.
To set up a media interview, contact: Eric Hoffman at firstname.lastname@example.org.